Medicamen Organics Limited (NSE:MEDIORG)
India · Delayed Price · Currency is INR 23.35
+1.10 (4.94%)
Jul 13, 2026, 3:13 PM IST
Medicamen Organics Revenue
In the fiscal year ending March 31, 2026, Medicamen Organics had annual revenue of 226.30M INR, down -40.74%. Medicamen Organics had revenue of 47.78M in the half year ending March 31, 2026, a decrease of -65.75%.
Revenue
226.30M
Revenue Growth
-40.74%
P/S Ratio
1.21
Revenue / Employee
n/a
Employees
114
Market Cap
273.20M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 226.30M | -155.57M | -40.74% |
| Mar 31, 2025 | 381.88M | 129.16M | 51.11% |
| Mar 31, 2024 | 252.72M | 31.25M | 14.11% |
| Mar 31, 2023 | 221.47M | 11.72M | 5.59% |
| Mar 31, 2022 | 209.75M | -40.72M | -16.26% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Remus Pharmaceuticals | 8.54B |
| Accent Microcell | 3.50B |
| Infinium Pharmachem | 1.90B |
| Zenith Drugs | 1.71B |
| Quest Laboratories | 1.26B |
| Sotac Pharmaceuticals | 1.02B |
| Sunrest Lifescience | 708.33M |
| Vilin Bio Med | 422.63M |